Zacks Investment Research upgraded shares of XOMA Corporation (NASDAQ:XOMA) from a hold rating to a strong-buy rating in a research report sent to investors on Friday. They currently have $33.00 price objective on the biotechnology company’s stock.

According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “

Several other equities analysts have also recently commented on the company. HC Wainwright restated a buy rating and set a $38.00 target price on shares of XOMA Corporation in a research report on Tuesday, November 7th. Wedbush upgraded XOMA Corporation from a neutral rating to an outperform rating and boosted their target price for the stock from $9.00 to $19.00 in a research report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $30.00.

XOMA Corporation (XOMA) traded up $1.82 during trading on Friday, reaching $30.44. The company had a trading volume of 222,700 shares, compared to its average volume of 145,464. XOMA Corporation has a twelve month low of $3.96 and a twelve month high of $31.03. The company has a debt-to-equity ratio of 3.53, a current ratio of 3.45 and a quick ratio of 3.45.

TRADEMARK VIOLATION NOTICE: “XOMA Corporation (XOMA) Raised to “Strong-Buy” at Zacks Investment Research” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at

A number of hedge funds have recently modified their holdings of the business. OxFORD Asset Management LLP bought a new stake in XOMA Corporation during the third quarter worth about $543,000. EAM Investors LLC bought a new stake in XOMA Corporation during the third quarter worth about $835,000. Finally, California Public Employees Retirement System lifted its stake in XOMA Corporation by 95.5% during the first quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 10,640 shares during the last quarter. 30.69% of the stock is owned by hedge funds and other institutional investors.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Get a free copy of the Zacks research report on XOMA Corporation (XOMA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.